I
Iuliana Shapira
Researcher at SUNY Downstate Medical Center
Publications - 48
Citations - 2164
Iuliana Shapira is an academic researcher from SUNY Downstate Medical Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 18, co-authored 45 publications receiving 1739 citations. Previous affiliations of Iuliana Shapira include Hofstra University & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Sara M. Tolaney,William T. Barry,Chau T. Dang,Denise A. Yardley,Beverly Moy,P. Kelly Marcom,Kathy S. Albain,Hope S. Rugo,Matthew J. Ellis,Iuliana Shapira,Antonio C. Wolff,Lisa A. Carey,Beth Overmoyer,Ann H. Partridge,Hao Guo,Clifford A. Hudis,Ian E. Krop,Harold J. Burstein,Eric P. Winer +18 more
TL;DR: Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events.
Journal ArticleDOI
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients—An Analysis of the Medical Literature
Stuart M. Lichtman,Hans Wildiers,Etienne Chatelut,Christopher Steer,Daniel R. Budman,Vicki A. Morrison,Brigitte Tranchand,Iuliana Shapira,Matti S. Aapro +8 more
TL;DR: Clinical trials need to incorporate an analysis of chemotherapy in terms of the pharmacokinetic and pharmacodynamic effects of aging, and data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient.
Journal ArticleDOI
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Sara M. Tolaney,Hao Guo,Sonia Pernas,William T. Barry,Deborah A. Dillon,Lauren L. Ritterhouse,Lauren L. Ritterhouse,Bryan P. Schneider,Fei Shen,Kit Fuhrman,Michele Baltay,Chau T. Dang,Chau T. Dang,Denise A. Yardley,Beverly Moy,P. Kelly Marcom,Kathy S. Albain,Hope S. Rugo,M. J. Ellis,Iuliana Shapira,Iuliana Shapira,Antonio C. Wolff,Lisa A. Carey,Beth Overmoyer,Ann H. Partridge,Clifford A. Hudis,Clifford A. Hudis,Clifford A. Hudis,Ian E. Krop,Harold J. Burstein,Eric P. Winer +30 more
TL;DR: With longer follow-up, adjuvant paclitaxel and trastuzumab is associated with excellent long-term outcomes, and distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously reported for larger tumors.
Journal ArticleDOI
Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.
TL;DR: This first report of the use and clinical efficacy of eculizumab, an inhibitor of complement activation, in the treatment ofCAPS demonstrates both the importance of complement (specifically, terminal complement components) in the pathogenesis of CAPS and the therapeutic benefit of complement inactivation.
Journal ArticleDOI
Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
Iuliana Shapira,Michaela Oswald,J.L. Lovecchio,Houman Khalili,A.W. Menzin,J.S. Whyte,L. Dos Santos,Sharron Liang,Tawfiqul Bhuiya,Mary Keogh,C. Mason,Keith Sultan,Daniel R. Budman,Peter K. Gregersen,Annette Lee +14 more
TL;DR: The preliminary data support the utility of circulating plasma miRNAs to distinguish women with ovarian cancer from those with a benign mass and identify women likely to benefit from currently available treatment for serous epithelial ovarian cancerFrom those who may not.